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Carnitine shuttleCarnitine acyltransferases catalyze the reversible conversion of acyl-CoAs into acylcarnitine esters. This
family includes the mitochondrial enzymes carnitine palmitoyltransferase 2 (CPT2) and carnitine
acetyltransferase (CrAT). CPT2 is part of the carnitine shuttle that is necessary to import fatty acids into mi-
tochondria and catalyzes the conversion of acylcarnitines into acyl-CoAs. In addition, when mitochondrial
fatty acid β-oxidation is impaired, CPT2 is able to catalyze the reverse reaction and converts accumulating
long- and medium-chain acyl-CoAs into acylcarnitines for export from the matrix to the cytosol. However,
CPT2 is inactive with short-chain acyl-CoAs and intermediates of the branched-chain amino acid oxidation
pathway (BCAAO). In order to explore the origin of short-chain and branched-chain acylcarnitines that
may accumulate in various organic acidemias, we performed substrate speciﬁcity studies using puriﬁed re-
combinant human CrAT. Various saturated, unsaturated and branched-chain acyl-CoA esters were tested
and the synthesized acylcarnitines were quantiﬁed by ESI-MS/MS. We show that CrAT converts short- and
medium-chain acyl-CoAs (C2 to C10-CoA), whereas no activity was observed with long-chain species.
Trans-2-enoyl-CoA intermediates were found to be poor substrates for this enzyme. Furthermore, CrAT
turned out to be active towards some but not all the BCAAO intermediates tested and no activity was
found with dicarboxylic acyl-CoA esters. This suggests the existence of another enzyme able to handle the
acyl-CoAs that are not substrates for CrAT and CPT2, but for which the corresponding acylcarnitines are
well recognized as diagnostic markers in inborn errors of metabolism.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Carnitine acyltransferases catalyze the transfer of acyl groups be-
tween coenzyme A (CoA) and carnitine. The carnitine acyltransferase
family is crucial in the catabolism of fatty acids and includes four
members: carnitine palmitoyltransferases 1 and 2 (CPT1 and CPT2),
carnitine octanoyltransferase (CrOT) and carnitine acetyltransferase
(CrAT). Prior to mitochondrial β-oxidation, long-chain fatty acids are
activated to CoA esters. However, these large acyl-CoAs are unable to
cross the inner mitochondrial membrane and have to be convertedd oxidation; CPT1, carnitine
nsferase 2; CrAT, carnitine
mCrAT, mitochondrial CrAT;
peroxisomal CrAT
ersity of Lisbon, Av. Prof. Gama
; fax: +351 217946491.
).
thors.
rights reserved.into the respective carnitine ester by CPT1, localized within the outer
mitochondrial membrane. Carnitine/acylcarnitine translocase (CACT)
is responsible for the transport of the long-chain acylcarnitines across
the inner mitochondrial membrane whereas CPT2, associated with the
inner aspect of the inner mitochondrial membrane, catalyzes their
reconversion to acyl-CoAs, which can then undergo β-oxidation [1].
The other two members of the acyltransferase family, CrAT and
CrOT have preference for short- and medium-chain substrates,
respectively. Both are soluble proteins found in peroxisomes but
while CrOT only exists in this organelle, CrAT is also found in the
mitochondrial matrix [2–5]. Very long-chain, branched-chain and
long-chain dicarboxylic fatty acids undergo β-oxidation in the perox-
isomes. The medium- and short-chain acyl-CoAs that result from this
oxidation are converted to carnitine esters, by CrOT and peroxisomal
CrAT. This allows the export of these intermediates to the cytosol and
further import into the mitochondria for complete oxidation [6]. In
mitochondria CrAT has a role in the maintenance of the acyl-CoA/CoA
pool [6,7] and it has been recently described as a modulator of whole
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a muscle-speciﬁc CrAT knockout mouse model [8]. The structural stud-
ies performed with the human CrAT and the resolution of the 3D struc-
ture of this enzyme were major advances in the understanding of the
catalytic mechanism of acyltransferase enzyme class [9,10].
It is now established that CPT2 is able to produce a net ﬂux in the
reverse direction, converting medium- and long-chain acyl-CoAs into
the respective acylcarnitine intermediates [11–13]. This is particular-
ly important in patients with a genetic or acquired mitochondrial
fatty acid β-oxidation (mFAO) disorder, where acyl-CoAs accumulate
intramitochondrially. CPT2 catalyzes the synthesis of these com-
pounds into acylcarnitines that are further exported to the cytosol
by CACT [14]. These acylcarnitines are ultimately exported to the
plasma via a still unknown mechanism and are important biomarkers
of inborn errors affecting mFAO or branched-chain amino acid metab-
olism [15,16].
While CPT2 is responsible for the synthesis of medium- and
long-chain acylcarnitines [11–13], the short- and branched-chain
acylcarnitine intermediates require another acyltransferase for their
synthesis. CrAT from mouse liver and pigeon breast as well as the re-
combinant CrAT from rat, have been described to catalyze the synthe-
sis of carnitine esters from acyl-CoAs with chain length from C2 to
C10-CoA [17–20] and the human enzyme (puriﬁed from liver) also
shows some activity with longer chain length substrates (C12 to
C14-CoA) [21]. The lack of a thorough study on the human forms of
CrAT prompted us to further investigate the substrate speciﬁcity of
this enzyme, not only for the straight-chain acyl-CoAs, but also for
the branched-chain amino acid oxidation (BCAAO) intermediates. In
this paper we present experimental evidence that provide new in-
sights into the role of CrAT in the formation of acylcarnitines. Further-
more we could conﬁrm that trans-2-enoyl-CoAs are poor substrates
for the enzymes from the carnitine acyltransferase family.
2. Materials and methods
2.1. Materials
The Zymoclean gel DNA recovery kit was purchased from Zymo
Research (Irvine, California, USA). The Escherichia coli strain
BL21(DE3) was obtained from Invitrogen (Carlsbad, California,
USA). Peptone and yeast extract were obtained from Difco Laborato-
ries Inc. (Detroit, MI). The HisLink™ protein puriﬁcation resin was
obtained from Promega (Madison, USA). The substrate trans-2-C5:
1-CoA was enzymatically synthesized as described by Rasmussen
et al. [22]. All other CoA esters were obtained from Sigma-Aldrich
(St. Louis, MO, USA) and prepared in MES buffer, pH 6.0. Human
serum albumin, bovine serum albumin, L-carnitine and acetylchloride
were obtained from Sigma-Aldrich (St. Louis, MO, USA). All other
chemicals were of analytical grade.
2.2. Construction of the expression plasmids
The sequences corresponding to the mitochondrial (amino acids
30 to 626) and peroxisomal (amino acids 22 to 626) CrAT (mCrAT
and pCrAT, respectively) were ampliﬁed by PCR using human ﬁbro-
blast cDNA as a template. The forward primers were designed includ-
ing an NdeI restriction site (5′-TATATCATATGAAGGCTTCCAGCCGC
TTCAA-3′ and 5′-TATATCATATGGCACACCAGGATGCACTGCCACG-3′,
respectively for the mCrAT and pCrAT). The same reverse primer
was used for both mCrAT and pCrAT (5′-TATATGGATCCTCCTAG
GGGCTCAGAGCTTG-3′). The PCR-product was ﬁrst cloned in the
pGEM-T vector. After digestion with NdeI and SalI (located in
pGEM-T) the product was cloned in frame with an N-terminal histi-
dine tag between the NdeI and XhoI sites of the pET19b expression
vector. Conﬁrmation of the sequence was performed by direct se-
quencing and the plasmids were used to transform E. coli BL21(DE3).2.3. Heterologous expression and puriﬁcation of the mitochondrial and
peroxisomal carnitine acetyltransferases
Histidine tagged mCrAT and pCrAT were expressed in E. coli
BL21(DE3) in Terriﬁc Broth medium (12 g/L tryptone, 24 g/L yeast
extract, 8 g/L glycerol and 25 mM potassium phosphate buffer
pH 7.5) for 16 h at 22 °C. The enzymes were puriﬁed on HisLink pro-
tein puriﬁcation resin according to the manufacturer's protocol. The
presence of the protein in each fraction was accessed by immediately
measuring the activity which was quantiﬁed as the reduction of
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB). The reaction mixture
contained 100 mM Tris–HCl pH 8.0, 1 mM EDTA, 5 mM L-carnitine,
0.2 mM DTNB and 20 μL of puriﬁed protein 50 times diluted. The re-
action was started by the addition of acetyl-CoA at a ﬁnal concentra-
tion of 0.2 mM. The reduction of DTNB was followed in time on a
spectrophotometer (Uvicon) at 412 nm. The fractions containing
CrAT activity were pooled and protein concentration was determined
using the bicinchoninic acid assay [23] and human serum albumin as
standard. Glycerol 50% was added to the enzyme fractions which
were stored at −80 °C.
2.4. Determination of mitochondrial and peroxisomal carnitine
acetyltransferase substrate speciﬁcities
Carnitine acetyltransferase activity was determined using the meth-
od described by van Vlies and co-workers for CPT1 [24]. The standard
assay mixture contained 150 mM potassium chloride, 25 mM Tris–HCl
pH 7.4, 2 mM EDTA, 10 mM potassium phosphate buffer pH 7.4, 1 mg/
mL bovine serum albumin (BSA) essentially fatty acid free, 500 μM
L-carnitine and 25 μM of each acyl-CoA to a ﬁnal volume of 150 μL. The
reaction was initiated by the addition of 5 μL of enzyme (approximately
30 ng of protein per assay) and was allowed to proceed at 37 °C. After
10 min incubation, the reaction was terminated by adding 750 μL
acetonitrile containing 50 pmol d3-propionylcarnitine (C3), 50 pmol
d3-octanoylcarnitine (C8) and 25 pmol d3-palmitoylcarnitine (C16) in-
ternal standards. After derivatization of the produced acylcarnitines
with 1-butanol/acetylchloride 4/1 (v/v), these intermediateswere quan-
tiﬁed by Electrospray Ionization Tandem Mass Spectrometry (ESI-MS/
MS). The purity of the acyl-CoAs was initially conﬁrmed by reverse
phase high performance liquid chromatography (HPLC). The data
obtained by ESI-MS/MS for all the short branched-chain acyl-CoAs was
conﬁrmed by ultra-performance liquid chromatography (UPLC) tandem
MS, essentially as described elsewhere [25].
2.5. Determination of the kinetic parameters of mitochondrial and
peroxisomal carnitine acetyltransferases
The kinetic parameters (Km and Vmax) for mitochondrial and
peroxisomal CrAT were determined using C2-CoA, C4-CoA and
trans-2-C4:1-CoA as substrates by measuring their activities in the
absence and presence of different concentrations of each substrate
(0–1.3 mM). Activity was assessed as described above. Non-linear re-
gression was determined with the GraphPad Prism 5 software and
the Michaelis–Menten equation was used to determine the kinetic
parameters.
3. Results
3.1. Determination of the substrate speciﬁcity of the mitochondrial and
peroxisomal carnitine acetyltransferases
We used recombinant human mitochondrial and peroxisomal
CrAT (mCrAT and pCrAT, respectively) for the determination of the
substrate speciﬁcity of both isoforms. Both mCrAT and pCrAT re-
vealed identical substrate speciﬁcity proﬁles for all substrates and
therefore we only show the results obtained with mCrAT. CrAT was
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(C8-C10) acyl-CoAs (Fig. 1). The enzyme did show some activity
with acyl-CoAs of longer chain length including C12- and C14-CoA,
but not with C16-CoA (Fig. 1). Interestingly, trans-2-enoyl-CoAs,
including mFAO and BCAAO intermediates such as trans-2-ene-C4-
CoA (crotonyl-CoA, trans-2-C4:1-CoA), trans-2-ene-3-methyl-C4-
CoA (3-methylcrotonyl-CoA), and trans-2-ene-2-methyl-C4-CoA
(tiglyl-CoA, trans-2-C5:1-CoA), were found to be poor substrates for
CrAT when compared with the straight-chain C4-CoA intermediate
(Fig. 1 and Fig. 2).
The degradation pathways of the different BCAA involve various
branched-chain acyl-CoA intermediates. We tested the activity of CrAT
with several of these compounds as well as with some intermediates
involved in dicarboxylic acid oxidation, peroxisomal β-oxidation and
ketone body synthesis (Fig. 2). CrAT was found to be active with most
of the substrates tested. The branched-chain acyl-CoAs had a much
lower afﬁnity towards CrAT than the straight-chain equivalents
(Figs. 1 and 2). Remarkably, CrAT did not display activity with
3-hydroxy-3-methylglutaryl-CoA, 2-methylacetoacetyl-CoA and dicar-
boxylic acyl-CoAs (malonyl-, methylmalonyl-, succinyl- and glutaryl-
CoA) (Fig. 2).
3.2. Determination of the enzymatic kinetic parameters of mitochondrial
and peroxisomal CrAT
We determined the kinetic parameters of mCrAT and pCrAT (Km
and Vmax) using acetyl-CoA (C2-CoA) as a substrate. Facing the fact
that enoyl-CoAs are poor substrates for CrAT, we performed a
comparative analysis of the kinetic parameters of the enzyme with
C4:0-CoA versus trans-2-C4:1-CoA. Employing non-linear regression142.6
56.1
235.9
Fig. 1.Mitochondrial CrAT (mCrAT) activity with saturated and unsaturated straight-chain
pmol/(min μg) for the acyl-CoA tested. The symbol n.d. denotes below the limit of detection
cates of three independent experiments.to the Michaelis–Menten equation, we found that mCrAT has lower
afﬁnity towards C2-CoA (Km=240 μM) than the peroxisomal en-
zyme pCrAT (Km=78 μM) (Table 1). The afﬁnity of both enzymes
for C4:0-CoA and trans-2-C4:1-CoA was in the same order of magni-
tude. However, the catalytic efﬁciency (Vmax/Km) of the enzyme
with trans-2-C4:1-CoA was approximately 100-fold lower than for
C4:0-CoA (Table 1). Similar results were observed with the peroxi-
somal enzyme (results not shown).
4. Discussion
In the light of its crucial role in mFAO, the carnitine acyltransferase
family has been extensively studied throughout the years. A particu-
larly large number of reports have been published concerning the
function and structure of carnitine acetyltransferase [6,8–10,26,27].
However, most of what is known about its substrate speciﬁcity was
investigated with non-human sources of the enzyme [17–20] or was
exclusively focused on the straight-chain substrates [21].
In patients suffering frommFAO and BCAAO disorders, the reverse
acyltransferase reaction is a critical step for the clearance of the accu-
mulating acyl units within the mitochondria. We recently demon-
strated in an in vitro system that CPT2 is able to reverse the
direction of the enzyme reaction for medium- and long-chain
acyl-CoAs but no activity is found with short-chain acyl-CoAs or
with the BCAAO intermediates [13]. However, some of these straight
short-chain and branched-chain acylcarnitines are commonly found
in the plasma of patients with mFAO and BCAAO disorders and
may be used as biomarkers for the newborn screening and further
diagnosis. The proposed candidate to synthesize these short- and
branched-chain acylcarnitines is CrAT, the other acyltransferase780.7
593.0
366.5
0.8
0.2
3.1
0.9
acyl-CoAs. The value in front of each bar corresponds to the mean activity expressed in
. Error bars indicate the standard deviation (SD). Data shown are mean±SD of dupli-
0.6
33.3
1.0
0.9
9.8
1.3
35.8
13.4
2.5
6.8
7.3
0
Fig. 2.Mitochondrial CrAT (mCrAT) activity with acyl-CoAs from A) valine degradation pathway; B) isoleucine degradation pathway; C) leucine degradation pathway; D) dicarbox-
ylic acid derivatives; E) peroxisomal intermediates and F) ketone body metabolites. The value in front of each bar corresponds to the mean activity expressed in pmol/(min μg) for
the acyl-CoA tested. The symbol n.d. denotes below the limit of detection. Error bars indicate the standard deviation. Data shown are mean±SD of duplicates of three independent
experiments.
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in order to clarify the origin of these metabolites, we performed
substrate speciﬁcity studies using puriﬁed recombinant human
mitochondrial and peroxisomal CrAT.
As described previously [21], we found that the human mCrAT
handles acyl-CoAs with a chain length ranging from 2 to 14 carbon
atoms, with C3-CoA as the most efﬁcient substrate (Fig. 1). Surpris-
ingly, the activity of mCrAT with C6-CoA was consistently lower
than with C8-CoA. The opposite has been found for glycine-N-
acyltransferase which has virtually no activity with C8 [28]. We
could not ﬁnd an explanation for this ﬁnding which nevertheless
was already reported for the mouse enzyme [18,19]. The mitochon-
drial CrAT had hardly any activity with C12- and C14-CoA, and had
no detectable activity with C16-CoA (Fig. 1). The peroxisomal CrATTable 1
Kinetic constants of mitochondrial and peroxisomal CrAT (mCrAT and pCrAT, respec-
tively), using acetyl-CoA (C2-CoA) as a substrate. Comparative analysis of the kinetic
constants and catalytic efﬁciency (Vmax/Km) of mCrAT with butyryl-CoA (C4:0-CoA)
versus trans-2-butenoyl-CoA (trans-2-C4:1-CoA). Analysis was performed with the
GraphPad Prism 5 software using the non-linear regression of the Michaelis–Menten
equation. Data shown are mean±SD of duplicates of at least two independent
experiments.
Protein Substrate Km
(μM)
Vmax
[nmol/(min μg)]
Vmax/Km
[1/(min μg)]
mCrAT C2-CoA 240±47 2.5±0.2 –
pCrAT C2-CoA 78±18 4.4±0.3 –
mCrAT C4-CoA 499±44 10.7±0.4 2.1×10−5
mCrAT Trans-2-C4:1-CoA 590±129 0.13±0.01 2.2×10−7behaved essentially as the mitochondrial enzyme, showing an identi-
cal substrate speciﬁcity proﬁle (results not shown).
Interestingly, acyl-CoAs with the same chain-length but with a
trans double bond at the C2 position turned out to be poor substrates
for CrAT, showing a catalytic efﬁciency approximately 100-fold lower
than the corresponding straight-chain acyl-CoA (Table 1). We had
previously observed a similar phenomenon for CPT2, suggesting
that the trans-2-enoyl-CoA intermediates may interfere with the cat-
alytic mechanism of acyltransferases [13]. The catalytic mechanism of
acyltransferases involves a nucleophilic attack that leads to the for-
mation of a tetrahedral intermediate anion (Fig. 3A) (for review see
[29]). The existence of a double bond at the second position may
cause resonance and lead to a distribution of the positive charge,
which makes the carbon atom of the carbonyl group less positive.
The charge displacement will likely hamper the nucleophilic attack
that always takes place at a positive center (Fig. 3B). This could lead
to the inhibition of the tetrahedral intermediate formation which
consequently inhibits the acylcarnitines synthesis. We speculate
that this interference may explain why the trans-2-enoyl-CoAs are
poor substrates for CPT2 and CrAT.
A similar decrease in CrAT activity was also observed with
acyl-CoAs in which a methyl group is located at the second position.
This is evidenced when comparing the activity obtained with the
substrates 2-methylacetoacetyl-CoA and 2-methylbutyryl-CoA with
acyl-CoAs of similar structure but lacking the methyl group at C2
(acetoacetyl-CoA and isovaleryl-CoA, respectively) (Fig. 2). Therefore,
similar to trans-2-enoyl-CoAs, we suggest that a methyl group located
at the second carbon of the acyl unit may interfere with the catalytic
mechanism of CrAT.
AB
Fig. 3. Schematic representation of the catalytic mechanism of acyltransferases. A) Mechanism of acylcarnitine formation. The catalytic histidine 343 acts as a general base to extract
the proton from the hydroxyl group of carnitine or the thiol group of CoA supporting the nucleophilic attack between carnitine and the acyl-CoAs. The tetrahedral intermediate
formed is probably stabilized by the interaction of the oxyanion with both carnitine and the hydroxyl group of serine 554. Adapted from [29]. B) Detail of the nucleophilic
group of the substrates C4:0-CoA and trans-2-C4:1-CoA. The double bond in the enoyl-CoA intermediate may cause resonance in the molecule which leads to the displacement
of the positive charge and hampers the nucleophilic attack (crossed arrow).
777S. Violante et al. / Biochimica et Biophysica Acta 1832 (2013) 773–779The carnitine acetyltransferases displayed activity with some but
not all the branched-chain acyl-CoAs tested. Isobutyryl-CoA, a metab-
olite in the degradation of valine (Fig. 4), accumulates in patients
with isobutyryl-CoA dehydrogenase deﬁciency as well as in patients
with the multiple acyl-CoA dehydrogenation defect (MADD). The
isobutyryl-moiety is found in the plasma of these patients as the
respective carnitine intermediate, i.e. isobutyrylcarnitine [30], which
according to our results can be synthesized by CrAT (Fig. 2A). CrAT
is also able to convert 3-hydroxyisobutyryl-CoA into the respective
3-hydroxyisobutyrylcarnitne (Fig. 2A). This intermediate is character-
istic of 3-hydroxyisobutyryl-CoA hydrolase deﬁciency [31].
Among the acyl-CoAs of the isoleucine degradation pathway (Fig. 4),
the highest CrAT activity was observed with 2-methylbutyryl-CoA
(Fig. 2B). This is the intermediate that accumulates in short
branched-chain acyl-CoA dehydrogenase (SBCAD) deﬁciency and the
respective acylcarnitine is the biomarker for this disease [32]. Although
tiglyl-CoA and 2-methyl-3-hydroxybutyryl-CoA were found to be poor
substrates for CrAT, we did ﬁnd some conversion to the respectiveacylcarnitines (Fig. 2B). These acylcarnitine intermediates are usu-
ally found in the plasma of patients suffering from 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase deﬁciency [33,34] and according
to our results, CrATmay be the enzyme responsible for their formation.
The metabolite 2-methylacetoacetylcarnitine has never been reported
in the plasma of patients with β-ketothiolase deﬁciency, which is in
line with our ﬁnding that CrAT is not active with this compound.
Isovaleryl-CoA is a metabolite in the leucine degradation pathway
(Fig. 4) and accumulates in cases of isovaleryl-CoA dehydrogenase deﬁ-
ciency (isovaleric acidemia), which can be diagnosed by the elevation of
isovalerylcarnitine in plasma [35,36]. Indeed, isovaleryl-CoAwas shown
to be a good substrate for CrAT (Fig. 2C), which indicates that this is
the enzyme likely responsible for its conversion to the corresponding
acylcarnitine. Concerning the remaining intermediates of the leu-
cine pathway, CrAT showed some activity towards 3-methylcrotonyl-
CoA but none when 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)
was studied (Fig. 2C). Unfortunately 3-hydroxyisovaleryl-CoA and
3-methylglutaconyl-CoA were not available and thus could not be
Isoleucine 
2-oxo-3-methylvaleric acid
2-Methylbutyryl-CoA
Tiglyl-CoA (C5:1)
2-Methyl-3OH-butyryl-CoA
2-Methylacetoacetyl-CoA
Propionyl-CoA Acetyl-CoA
SBCAD
Crotonase
MHBD
Leucine 
2-oxo-isocaproic acid
Isovaleryl-CoA
3-Methylcrotonyl-CoA 
3-Methylglutaconyl-CoA
3OH-3-Methylglutaryl-CoA
Acetoacetic acid
IVD
MCC
Valine
2-oxo-isovaleric acid
Isobutyryl-CoA
Methacrylyl-CoA 
3OH-Isobutyryl-CoA
3OH-isobutyric acid
Methylmalonic semialdehyde
ACAD8
Crotonase
β-ketothiolase
3MGHHIBCH
HIBADH HMG-CoA Lyase
Methylmalonyl-CoA
Succinyl-CoA
Fig. 4. Catabolic pathways of the branched-chain amino acids valine, isoleucine and leucine. The substrates for which CrAT activity was tested are in white boxes and the ones
that are not substrates for the enzyme are represented in grey boxes. The names of the enzymes are shown on the right. ACAD8: isobutyryl-CoA dehydrogenase;
HIBCH: 3-hydroxyisobutyryl-CoA dehydrogenase; HIBADH: 3-hydroxyisobutyrate dehydrogenase; SBCAD: short branched-chain acyl-CoA dehydrogenase; MHBD: 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase; IVD: isovaleryl-CoA dehydrogenase; MCC: 3-methylcrotonyl-CoA carboxylase; 3MGH: 3-methylglutaconyl-CoA hydratase.
778 S. Violante et al. / Biochimica et Biophysica Acta 1832 (2013) 773–779tested. All neonatal screening programs use 3-hydroxyisovalerylcarnitine
as a marker of 3-methylcrotonyl-CoA carboxylase deﬁciency but the
mechanism by which it is formed has not been elucidated so far.
Patients with a deﬁciency of HMG-CoA lyase do not accumulate
HMG-carnitine but are characterized by measurable quantities of
3-methylglutarylcarnitine and 3-hydroxyisovalerylcarnitine. To our
knowledge no report on the occurrence of 3-methylglutaconylcarnitine
has ever been reported.
We also investigated CrAT activity with short-chain dicarboxylic
acyl-CoAs (Fig. 2D). Unexpectedly, no activity was found with any
of the substrates tested (malonyl-, methylmalonyl-, succinyl- and
glutaryl-CoA). The respective acylcarnitines are commonly found in
several disorders such as malonic acidemia (malonyl-CoA decarbox-
ylase deﬁciency), methylmalonic acidemia (methylmalonyl-CoA mu-
tase deﬁciency), combined malonic and methylmalonic acidemia
(with mutations in the gene ACSF3), succinyl-CoA ligase deﬁciency
(due to mutations in the SUCLG1 and SUCLA2 genes) and glutaric
acidemia (glutaryl-CoA dehydrogenase deﬁciency) [37–41]. There-
fore, as CrAT does not seem to be responsible for the formation of
these acylcarnitines, another enzyme must handle the intermediates
accumulating in the above mentioned inherited metabolic disorders.
In order to investigate if dicarboxylic acylcarnitines could be pro-
duced using another enzyme source, we incubated human liver and
kidney homogenates with each of the dicarboxylic acyl-CoAs. Surpris-
ingly, none of the expected dicarboxylic acylcarnitines were detected
(results not shown). Obviously further investigations are necessary to
resolve this issue.
Finally, we tested some peroxisomal intermediates derived from
pristanic acid oxidation and some ketone body derivatives. Peroxi-
somal β-oxidation of pristanic acid yields the intermediate 4,8-
dimethylnonanoyl-CoA (DMN-CoA), probably converted by CrOT
into its carnitine ester [42] and exported to the cytoplasm. Further ox-
idation requires the mitochondrial import of DMN-carnitine and its
reconversion to DMN-CoA. One additional cycle of β-oxidation in mi-
tochondria leads to the formation of 2,6-dimethylheptanoyl-CoA
(DMH-CoA). We previously demonstrated that CPT2 is active withDMN-CoA but not with DMH-CoA [13]. Now, we show that both sub-
strates are converted to the respective acylcarnitine by CrAT (Fig. 2E).
The ketone body derivatives acetoacetyl-CoA and 3-hydroxybutyryl-
CoA were also tested and CrAT was found to be active with both sub-
strates (Fig. 2F). The carnitine ester 3-hydroxybutyrylcarnitine was
proposed to be an important player in insulin resistance in mice
[43] and has recently been described as a metabolite in ketone body
metabolism [44]. Furthermore, L-3-hydroxybutyrylcarnitine is also
known to accumulate in short-chain 3-hydroxyacyl-CoA dehydroge-
nase (SCHAD) deﬁcient patients [45]. We observed that mCrAT main-
ly produced L-3-hydroxybutyrylcarnitine from a racemic mixture of
D- and L-3-hydroxybutyryl-CoA, suggesting that its activity is higher
with the L-isoform.
5. Conclusions
In summary, both mitochondrial and peroxisomal CrAT have
been found to be able to catalyze the acylcarnitine synthesis from
straight-chain acyl-CoAs with chain length up to ten carbon atoms.
Furthermore, we have shown that trans-2-enoyl-CoA intermediates
are poor substrates for CrAT, similar to what has been previously
reported for CPT2, thus suggesting that the catalytic mechanism of
acyltransferases is hamperedby the presence of a double bond at the sec-
ond position of the substrate carbon chain. We further show that CrAT is
active towards the intermediates of the BCAAO pathway that are com-
monly found in the acylcarnitine proﬁles of patients and with some per-
oxisomal intermediates derived from pristanic acid oxidation. For the
dicarboxylic acyl-CoA species that do not seem to be handled by CrAT,
but for which acylcarnitines are found in the plasma of patients, further
studies are necessary to disclose their underlying mode of synthesis.
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